NeuroOne Medical Technologies (NMTC) to Announce Earnings on Thursday

NeuroOne Medical Technologies (NASDAQ:NMTC) will likely be releasing its Q3 2026 results before the market opens on Thursday, August 13th. Analysts expect the company to announce earnings of ($0.5833) per share and revenue of $2.5470 million for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earning report for the latest details on the call scheduled for Thursday, August 13, 2026 at 8:30 AM ET.

NeuroOne Medical Technologies (NASDAQ:NMTC) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.02). The firm had revenue of $1.86 million for the quarter, compared to analysts’ expectations of $2.58 million. NeuroOne Medical Technologies had a negative net margin of 68.35% and a negative return on equity of 99.43%. On average, analysts expect NeuroOne Medical Technologies to post $-0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NeuroOne Medical Technologies Trading Down 2.4%

NeuroOne Medical Technologies stock opened at $1.65 on Thursday. The firm’s 50 day simple moving average is $2.81 and its 200 day simple moving average is $3.96. The firm has a market capitalization of $14.36 million, a PE ratio of -1.94 and a beta of 0.61. NeuroOne Medical Technologies has a 1-year low of $1.61 and a 1-year high of $6.96.

Insider Activity at NeuroOne Medical Technologies

In other news, Director Mark Christianson sold 10,000 shares of the stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $3.18, for a total value of $31,800.00. Following the transaction, the director owned 20,692 shares of the company’s stock, valued at $65,800.56. This represents a 32.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 11.80% of the stock is owned by insiders.

Institutional Trading of NeuroOne Medical Technologies

A number of hedge funds have recently made changes to their positions in NMTC. Vanguard Group Inc. grew its position in NeuroOne Medical Technologies by 31.2% in the third quarter. Vanguard Group Inc. now owns 1,578,237 shares of the company’s stock worth $1,403,000 after acquiring an additional 375,639 shares in the last quarter. Essex Investment Management Co. LLC purchased a new stake in NeuroOne Medical Technologies during the fourth quarter valued at about $143,000. Virtu Financial LLC purchased a new stake in NeuroOne Medical Technologies during the third quarter valued at about $88,000. Goldman Sachs Group Inc. bought a new stake in NeuroOne Medical Technologies during the first quarter worth about $84,000. Finally, XTX Topco Ltd bought a new stake in NeuroOne Medical Technologies during the second quarter worth about $51,000. 16.07% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently commented on NMTC. LADENBURG THALM/SH SH boosted their price target on shares of NeuroOne Medical Technologies from $1.60 to $8.00 and gave the company a “buy” rating in a research report on Wednesday, May 13th. Weiss Ratings upgraded NeuroOne Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 28th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, NeuroOne Medical Technologies currently has a consensus rating of “Hold” and a consensus price target of $11.67.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.